CURE and Therapix To Research Personalized Medicine and Cannabinoids

CURE Pharmaceutical (OTCQB:CURR) in partnership with Therapix Biosciences (NASDAQ:TRPX) entered into a research collaboration with the Israeli-based Assuta Medical Centers in order to collaborate to advance, research, develop and commercialize potential therapeutic products in the fields of personalized medicine and cannabinoids.
As quoted in the press release:

“As CURE focuses on targeting unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options, we are continuously looking to help bring new therapeutic cannabinoid-based products to market and further efforts toward the creation of personalized medicine,” said Robert Davidson, CEO of CURE Pharmaceutical. “Our new collaboration with Therapix and Assuta, two leading companies in Israel, a country that is at the forefront of cannabinoid-based research in the world, is the perfect place to start the development of these products.”
Dr. Ascher Shmulewitz, Chairman of Therapix, added, “CURE is the ideal partner for us to enter this promising field of cutting-edge personalized cannabinoid-based therapeutics. This deal has all the signs of a fruitful venture.”
As agreed to in the MOU, the Companies intend to formalize the pooling of professional, scientific, financial resources and expertise, in order to benefit from each of its respective advantages and capabilities to develop new therapeutic products in the fields of personalized medicine and cannabinoids. Specifically, CURE and Therapix will provide support and expertise in the development of pharmaceutical products, while Assuta will support the early research and development of potential projects through its research and facilities.

Click here to read the full press release.

Source: globenewswire.com